China-Originated Oncology Research Gains Attention at ASCO 2026

Quick Answer / What Happened

According to a June 9, 2026 Sanlian Lifeweek / Sanlian.CREATIVE report, Chinese oncology teams presented notable China-originated cancer research results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The report focused on data involving iza-bren, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in triple-negative breast cancer and esophageal squamous cell carcinoma, and used these results to describe a broader shift in China's oncology innovation: Chinese researchers are increasingly moving from followers and observers to active contributors on the global cancer research stage.

This update summarizes the Sanlian report. It does not independently evaluate the therapy or suggest that these results apply to any individual patient.

Why This Matters

The Sanlian report framed the ASCO presentations as part of a larger change in China's cancer drug development. It described a past period when Chinese oncology drug research often followed global innovation, and contrasted that with a current period in which Chinese original therapies and clinical research are reaching major international meetings.

The article quoted Peking University Cancer Hospital professor Shen Lin as saying that, in 2026, 10 to 11 innovative drugs or indications from clinical studies she led or participated in were expected to receive approval. The report presented this as a sign that China's original drug development is accelerating and that Chinese clinical teams are bringing more research to the world stage.

Triple-Negative Breast Cancer: Fudan University Shanghai Cancer Center Team

The Sanlian article described work led by Professor Wu Jiong and Professor Zhang Jian at Fudan University Shanghai Cancer Center involving patients with unresectable locally advanced or metastatic triple-negative breast cancer. The report described triple-negative breast cancer as a difficult breast cancer subtype with earlier onset, higher malignancy, and greater tendency toward metastasis.

According to the report, the phase III study compared the EGFR x HER3 bispecific ADC iza-bren with standard chemotherapy in patients who had already received prior conventional treatment and experienced disease progression. In February 2026, the study met dual primary endpoints, achieving positive results in both progression-free survival and overall survival.

According to the Sanlian report, at ASCO 2026 the iza-bren group showed a median progression-free survival of 8.5 months and, according to the report, reduced the risk of disease progression or death by 71% compared with standard chemotherapy. The report also stated median overall survival of 15.9 months and a 40% reduction in risk of death compared with standard chemotherapy.

Sanlian described the data as highly encouraging and quoted Professor Zhang Jian as presenting the phase III results as a breakthrough for a China-originated bispecific ADC in second-line and later treatment of triple-negative breast cancer.

Esophageal Squamous Cell Carcinoma: Peking University Cancer Hospital Team

The article also focused on esophageal squamous cell carcinoma, a disease area where China carries a large disease burden. Citing IARC/GLOBOCAN 2022 data, the report stated that China accounted for about 43.8% of new global esophageal cancer cases and 42.1% of related deaths in 2022, with esophageal squamous cell carcinoma being the most common subtype in China.

According to the Sanlian report, Professor Shen Lin of Peking University Cancer Hospital described a long-standing clinical challenge: in the past, when standard treatment failed, patients with esophageal squamous cell carcinoma often had very limited later-line options. The article framed China-led innovation as especially important because esophageal squamous cell carcinoma has lower incidence in Europe and the United States, leaving less global development momentum for this specific disease area.

At ASCO 2026, the report said a phase III study led by Professor Shen Lin disclosed positive results in both progression-free survival and overall survival. The study reported median progression-free survival of 4.17 months, more than twice that of the chemotherapy control group; objective response rate of 35.3%, nearly three times that of chemotherapy; and overall survival of 9.79 months, with, according to the report, a 36% reduction in risk of death compared with chemotherapy. The Sanlian article also noted that Professor Lu Zhihao of Peking University Cancer Hospital presented related results at the ASCO meeting.

From Observer to Global-Stage Contributor

The Sanlian report described ASCO as one of the world's most influential oncology meetings. It noted that iza-bren research in both triple-negative breast cancer and esophageal squamous cell carcinoma entered major ASCO presentation formats, including late-breaking abstract and oral presentation sessions.

The article also described a change in how Chinese researchers are received internationally. Professor Wu Jiong was quoted as saying that the ASCO presentation reflected the status and value of Chinese original drug innovation. According to Professor Wu Jiong's account in the Sanlian report, international organizers appeared surprised by the importance China now holds in first-in-class innovation. Professor Shen Lin described a shift in which global physicians increasingly approach Chinese teams after conferences to discuss upper gastrointestinal cancer research.

The report used this to frame a broader movement: Chinese oncology teams are no longer only learning from overseas innovation. In selected fields, they are presenting original research, driving clinical trials, and contributing China-based data to global cancer treatment discussions.

What International Patients Should Understand

For international patients and families, the main takeaway is not that one reported therapy is suitable for everyone. The more important point is that China's oncology ecosystem is changing quickly. Selected Chinese hospitals, clinical investigators, and drug developers are producing research that appears on major global oncology stages.

This can matter when families are comparing advanced cancer treatment options across countries. In selected cases, China may be worth reviewing not only for cost or timing, but also because certain China-originated therapies, clinical research pathways, and specialist teams may be relevant to a patient's diagnosis, treatment history, biomarker profile, and practical situation.

What This Does NOT Mean

This report does not mean every patient with triple-negative breast cancer, esophageal squamous cell carcinoma, or another cancer is suitable for iza-bren or any reported study pathway. It does not mean the same outcomes should be expected for individual patients. Relevance depends on diagnosis, stage, prior treatment, biomarker status, clinical condition, hospital availability, regulatory status, and treating-team review.

How CareNavigator Can Help Patients Evaluate Relevance

For patients and families who see an update like this and wonder whether it may be relevant to their own situation, CareNavigator helps turn the news into a practical decision pathway. We help patients clarify their current diagnosis, treatment bottleneck, and decision point; compare whether China has relevant hospital, specialist, and technology options worth reviewing; coordinate case review with appropriate medical teams; and support the broader journey across hospital communication, pathway comparison, logistics, and follow-up planning. The final medical judgment remains with licensed clinicians and the responsible hospital team.

Related CareNavigator Resources

• China Advanced Treatment Updates
• Why China
• How CareNavigator Helps
• China Treatment Navigation Guide
• CAR-T Cell Therapy in China
• How to Compare Cancer Hospitals in China Before You Decide

Source-Led Update Note

This article summarizes publicly available reporting and cited source materials about medical developments in China. It is not CareNavigator's independent clinical assessment of the therapy and should not be read as medical advice for any individual patient. CareNavigator helps patients and families understand whether a reported China-based pathway may be relevant, compare options that may be worth reviewing, and prepare for informed conversations with qualified medical teams. Patient eligibility, risks, benefits, availability, and treatment decisions should be assessed by licensed clinicians and the responsible medical institution.

Primary source: Sanlian Lifeweek / 三联生活周刊, Sanlian.CREATIVE article titled "与癌症赛跑的中国速度", published on WeChat on 2026-06-09. Original URL shown in the source note: https://mp.weixin.qq.com/s/X4sY2oYFhLRCVVJ6Vdjliw

Back to CareNavigator Insights